Y-mAbs Therapeutics, Inc. $YMAB Shares Purchased by Rhumbline Advisers

Rhumbline Advisers increased its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 4.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 53,909 shares of the company’s stock after acquiring an additional 2,457 shares during the quarter. Rhumbline Advisers owned approximately 0.12% of Y-mAbs Therapeutics worth $239,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Cubist Systematic Strategies LLC raised its stake in Y-mAbs Therapeutics by 223.9% during the first quarter. Cubist Systematic Strategies LLC now owns 155,522 shares of the company’s stock worth $689,000 after acquiring an additional 107,511 shares during the period. Bank of America Corp DE increased its stake in shares of Y-mAbs Therapeutics by 59.5% in the fourth quarter. Bank of America Corp DE now owns 127,159 shares of the company’s stock valued at $996,000 after purchasing an additional 47,439 shares during the period. Exchange Traded Concepts LLC increased its stake in shares of Y-mAbs Therapeutics by 107.9% in the first quarter. Exchange Traded Concepts LLC now owns 26,762 shares of the company’s stock valued at $119,000 after purchasing an additional 13,890 shares during the period. Nuveen LLC acquired a new stake in shares of Y-mAbs Therapeutics in the first quarter valued at approximately $498,000. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of Y-mAbs Therapeutics by 58.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 237,511 shares of the company’s stock valued at $1,052,000 after purchasing an additional 87,830 shares during the period. Institutional investors and hedge funds own 70.85% of the company’s stock.

Analyst Ratings Changes

YMAB has been the topic of several analyst reports. Brookline Capital Management lowered shares of Y-mAbs Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Wall Street Zen upgraded shares of Y-mAbs Therapeutics to a “hold” rating in a research note on Saturday, September 20th. Cantor Fitzgerald set a $8.60 price target on shares of Y-mAbs Therapeutics and gave the company a “neutral” rating in a research note on Tuesday, August 5th. Truist Financial set a $8.60 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 5th. Finally, Canaccord Genuity Group lowered shares of Y-mAbs Therapeutics from a “strong-buy” rating to a “hold” rating and dropped their price target for the company from $26.00 to $8.60 in a research note on Tuesday, August 5th. Eight research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Y-mAbs Therapeutics has a consensus rating of “Reduce” and a consensus target price of $9.62.

Y-mAbs Therapeutics Price Performance

NASDAQ YMAB opened at $8.61 on Friday. Y-mAbs Therapeutics, Inc. has a 12 month low of $3.55 and a 12 month high of $16.11. The firm has a market capitalization of $391.24 million, a PE ratio of -17.22 and a beta of 0.54. The company’s 50 day simple moving average is $7.61 and its 200 day simple moving average is $5.59.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Friday, August 8th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.20. The business had revenue of $19.52 million for the quarter, compared to analyst estimates of $18.40 million. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative return on equity of 24.60%. Sell-side analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.